PCP4L1

Across TCGA pan-cancer cohorts, PCP4L1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PCP4L1 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCP4L1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PCP4L1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and HNSC are the cancer types where PCP4L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.770	0.317	.008	8	view →
GBM	DFS	Quartile	All	0.933	0.609	.010	5	view →
HNSC	OS	Quartile	II,III,IV	0.925	1.000	.027	4	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.822	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PCP4L1–LUAD (OS)

Open the LUAD breakdown →